慢性髓性白血病治疗新药asciminib药理作用及临床评价  

Pharmacological effects and clinical evaluation of asciminib for chronic myeloid leukemia

作　　者：李春杏 刘丽艳 蔡金蕊 李妍[1] 李佳忆 刘桦[1] LI Chun-xing;LIU Li-yan;CAI Jin-rui;LI Yan;LI Jia-yi;LIU Hua(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China)

机构地区：[1]航天中心医院药剂科,北京100049

出　　处：《中国新药杂志》2022年第22期2223-2226,共4页Chinese Journal of New Drugs

摘　　要：慢性髓性白血病(chronic myeloid leukemia, CML)是一种起源于造血干细胞的恶性肿瘤,目前酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)作为CML的一线治疗虽获得较好临床疗效,但也有部分患者出现TKIs治疗失败或不耐受,2021年10月29日,美国FDA批准BCR-ABL1酪氨酸激酶变构抑制剂asciminib上市,对≥2种TKIs耐药或不耐受的CML患者提供治疗方案,临床研究显示疗效佳且耐受性好。本文就其药理作用、临床评价、安全性及其用法用量等进行综述。Chronic myeloid leukemia(CML) is a malignant tumor originating from hematopoietic stem cells. Currently, tyrosine kinase inhibitors(TKIs) have achieved good clinical efficacy as first-line treatment of CML. However, there are also some patients with TKIs treatment failure or intolerance. On October 29, 2021, FDA approved the marketing of asciminib, an allosteric inhibitor of BCR-ABL1 tyrosine kinase, to provide treatment for CML patients with ≥2 TKIs resistance or intolerance. Clinical studies have shown good efficacy and tolerability. This article reviews its pharmacological action, clinical evaluation, safety, usage and dosage.

关 键 词：慢性髓性白血病 asciminib 临床疗效 安全性 

分 类 号：R979.1[医药卫生—药品]